Glaxosmi. Pharma

GLAXO03 May 2024

Pharmaceuticals

₹

-9.70 (-0.46%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Glaxosmi. Pharma

Glaxosmi. Pharma

Pharmaceuticals

GLAXO03 May 2024

₹

-9.70 (-0.46%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
17-May-2023	D	Board has recommended a dividend of Rs. 32/- per equity share on face value of Rs.10 each for the year ended 31 st March 2023, subject to approval of members at 98th Annual General Meeting.	30-Jun-2023
16-May-2022	D	Board approved: 1. Dividend The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022.	07-Jul-2022
16-May-2022	D	Board approved: 1. Dividend The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022.	07-Jul-2022
18-May-2021	D	The Board has recommended a dividend of Rs. 30/- per equity share on face value of Rs.10 each for the year ended 31st March 2021, subject to approval of members at 96th Annual General Meeting.	19-Jul-2021
18-May-2020	D	The Board has approved the Audited Financial Statements (Standalone and Consolidated) for the year ended 31st March 2020, Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2020 and further the Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 each which includes a special dividend of Rs. 20 per share for this year. (Year ended 31st March 2019 Rs.20 per share).	17-Jul-2020
18-May-2020	D	The Board has approved the Audited Financial Statements (Standalone and Consolidated) for the year ended 31st March 2020, Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2020 and further the Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 each which includes a special dividend of Rs. 20 per share for this year. (Year ended 31st March 2019 Rs.20 per share).	17-Jul-2020
20-May-2019	D	The Board has recommended a dividend of Rs. 20/- per equity share on face value of Rs. 10 each for the year ended 31st March 2019. The dividend if approved by the shareholders will be paid on or after 22nd July 2019.	11-Jul-2019
24-May-2018	D	we are pleased to furnish the following information: 1. Dividend The Board has recommended a dividend of Rs. 35/- per equity share on face value of Rs. 10 each for the year ended 31st March 2018. The dividend if approved by the shareholders will be paid after 24th July 2018	13-Jul-2018
19-May-2017	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2017, inter alia, has recommended a dividend of 300% on the Equity Share capital i.e. Rs. 30/- per equity share for the year ended March 31, 2017. The dividend if approved by the shareholders will be paid after July 25, 2017.	14-Jul-2017
25-May-2016	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2016, inter alia, has transacted the following : 1. The Board has recommended a dividend of 500% on the Equity Share capital i.e. Rs. 50/- per equity share for the year ended March 31, 2016. The dividend if approved by the shareholders will be paid on or after July 28, 2016.	15-Jul-2016
18-May-2015	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2015, inter alia, has recommended a dividend of Rs. 62.50 per equity share for the fifteen month period ended March 31, 2015. The dividend if approved by the shareholders will be paid on or after August 01, 2015.	23-Jul-2015
18-Feb-2014	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2014, inter alia, have recommended the payment of a Dividend of Rs. 50/- per equity share for the year ended December 31, 2013.	03-Apr-2014
19-Feb-2013	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 19, 2013, inter alia, has recommended a Dividend of Rs. 50 per equity shares (Previous year : Rs. 45 per equity share).	04-Apr-2013
16-Feb-2012	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 16, 2012, inter alia, recommended a dividend of Rs. 45/- per equity share for the year ended December 31, 2011.	29-Mar-2012
14-Feb-2011	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2011, inter alia, recommends a dividend of Rs. 40/- per equity share for the year ended December 31, 2010.	14-Mar-2011
15-Feb-2010	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 15, 2010, inter alia, has recommended a Dividend of Rs. 30 per equity share (Previous year Rs. 22 per equity share and a special additional Dividend of Rs. 18 per equity share).	10-Mar-2010
18-Feb-2009	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2009, inter alia, has recommended the payment of a Dividend of Rs 22/- per equity share (Previous year Rs 18 per equity share) and a special additional Dividend of Rs 18 per equity share (Previous year Rs 18 per equity share). Sc Code - 600660 (As Per BSE Bulletin dated on 18.02.2009)	18-Mar-2009
18-Feb-2009	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2009, inter alia, has recommended the payment of a Dividend of Rs 22/- per equity share (Previous year Rs 18 per equity share) and a special additional Dividend of Rs 18 per equity share (Previous year Rs 18 per equity share). Sc Code - 600660 (As Per BSE Bulletin dated on 18.02.2009)	18-Mar-2009
22-Feb-2008	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 22, 2008, inter alia, has recommended the payment of a Dividend of Rs 18/- per equity share for the year ended December 31, 2007 and the Directors also recommend a special additional dividend of Rs 18/- per equity share.	02-Apr-2008
22-Feb-2008	D	GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 22, 2008, inter alia, has recommended the payment of a Dividend of Rs 18/- per equity share for the year ended December 31, 2007 and the Directors also recommend a special additional dividend of Rs 18/- per equity share.	02-Apr-2008
16-Feb-2007	D	170% Final Dividend	14-Mar-2007
16-Feb-2007	D	140% Special Additional Dividend	14-Mar-2007
06-Sep-2018	B	Trading Members of the Exchange are hereby informed that, GlaxoSmithKline Pharmaceuticals Limited has fixed the record date for the purpose of Bonus Issue. The transactions in the equity shares of the company would be on an ex-bonus basis with effect from the under mentioned date. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE GlaxoSmithKline Pharmaceuticals Limited (500660) RECORD DATE 13/09/2018 PURPOSE Issue of 01 (One) Bonus equity share of Rs.10/- each for every 01 (One) existing equity share of Rs.10/- each held. Ex-Bonus basis from Date & Sett. No. 11/09/2018 DR-116/2018-2019 Trading Members of the Exchange are requested to take of it.	13-Sep-2018	1:1
19-Apr-2024	BC	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve Pursuant to clause 29 &	17-May-2024
26-Dec-2023	BC	Closure of Trading window GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and app	12-Feb-2024
04-Oct-2023	BC	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Un-Audited Financial Resul	09-Nov-2023
30-May-2023	BC	AGM 26/07/2023 We wish to inform you that the Company Will hold the 98th Annual General Meeting ('AGM') on Wednesday, 26th July, 2023, through Video Conferencing / Other Audio Visual Means in acc	26-Jul-2023
26-Jun-2023	BC	Closure of Trading Window We wish to inform you that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company'	26-Jul-2023

Announcement Date17-May-2023

Ex Dividend Date30-Jun-2023

Dividend(%)320

Announcement Date16-May-2022

Ex Dividend Date07-Jul-2022

Dividend(%)300

Announcement Date16-May-2022

Ex Dividend Date07-Jul-2022

Dividend(%)600

Announcement Date18-May-2021

Ex Dividend Date19-Jul-2021

Dividend(%)300

Announcement Date18-May-2020

Ex Dividend Date17-Jul-2020

Dividend(%)200

Announcement Date18-May-2020

Ex Dividend Date17-Jul-2020

Dividend(%)200

Announcement Date20-May-2019

Ex Dividend Date11-Jul-2019

Dividend(%)200

Announcement Date24-May-2018

Ex Dividend Date13-Jul-2018

Dividend(%)350

Announcement Date19-May-2017

Ex Dividend Date14-Jul-2017

Dividend(%)300

Announcement Date25-May-2016

Ex Dividend Date15-Jul-2016

Dividend(%)500

Announcement Date18-May-2015

Ex Dividend Date23-Jul-2015

Dividend(%)625

Announcement Date18-Feb-2014

Ex Dividend Date03-Apr-2014

Dividend(%)500

Announcement Date19-Feb-2013

Ex Dividend Date04-Apr-2013

Dividend(%)500

Announcement Date16-Feb-2012

Ex Dividend Date29-Mar-2012

Dividend(%)450

Announcement Date14-Feb-2011

Ex Dividend Date14-Mar-2011

Dividend(%)400

Announcement Date15-Feb-2010

Ex Dividend Date10-Mar-2010

Dividend(%)300

Announcement Date18-Feb-2009

Ex Dividend Date18-Mar-2009

Dividend(%)220

Announcement Date18-Feb-2009

Ex Dividend Date18-Mar-2009

Dividend(%)180

Announcement Date22-Feb-2008

Ex Dividend Date02-Apr-2008

Dividend(%)180

Announcement Date22-Feb-2008

Ex Dividend Date02-Apr-2008

Dividend(%)180

Announcement Date16-Feb-2007

Ex Dividend Date14-Mar-2007

Dividend(%)170

Announcement Date16-Feb-2007

Ex Dividend Date14-Mar-2007

Dividend(%)140

No Rights has been declared by GLAXO

Book Closure

Record Date	Split Date	Purpose
17-May-2024	-	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve Pursuant to clause 29 &
12-Feb-2024	-	Closure of Trading window GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and app
09-Nov-2023	-	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Un-Audited Financial Resul
26-Jul-2023	-	AGM 26/07/2023 We wish to inform you that the Company Will hold the 98th Annual General Meeting ('AGM') on Wednesday, 26th July, 2023, through Video Conferencing / Other Audio Visual Means in acc
26-Jul-2023	-	Closure of Trading Window We wish to inform you that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company'

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Glaxosmithkline Pharmaceuticals Ltd ₹2,093.85(-9.70/-0.46%)	2,093.85	-9.70	35,471.08	67.72	55.81	22.92
Astrazeneca Pharma India Ltd ₹5,424.45(+90.60/1.70%)	5,424.45	+90.60	13,561.13	71.45	85.02	20.71
Bliss GVS Pharma Ltd ₹119.10(-10.10/-7.82%)	119.10	-10.10	1,246.87	56.07	18.27	1.28
Cipla Ltd ₹1,424.75(+5.20/0.37%)	1,424.75	+5.20	115,033.60	54.70	34.98	4.44
Amrutanjan Health Care Ltd ₹775.50(-11.10/-1.41%)	775.50	-11.10	2,242.02	27.78	50.95	8.56
Abbott India Ltd ₹26,144.45(-459.90/-1.73%)	26,144.45	-459.90	55,556.96	15.92	48.50	17.87

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	804.98	953.38	738.02	782.16	799.11	905.61
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	804.98	953.38	738.02	782.16	799.11	905.61
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	28.34	28.47	54.10	38.37	23.60	22.16
Total Income	833.32	981.85	792.12	820.53	822.71	927.77
Total Expenditure	750.78	666.80	596.77	615.40	582.68	648.69
PBIDT	82.54	315.05	195.35	205.13	240.03	279.08
Interest	0.32	0.43	0.28	0.65	0.09	0.39
PBDT	82.22	314.62	195.07	204.48	239.94	278.69
Depreciation	17.11	18.11	16.36	17.18	16.41	16.36
Tax	31.32	90.60	52.63	56.58	69.01	73.40
Deferred Tax	-11.70	-9.63	-4.50	-0.76	-9.51	-4.63
Reported Profit After Tax	45.49	215.54	130.58	131.48	164.03	193.56
Extra-ordinary Items	-131.99	0.00	12.21	7.26	-7.86	0.00
Adjusted Profit After Extra-ordinary item	177.48	215.54	118.37	124.22	171.89	193.56

EPS (Unit Curr.)	2.69	12.72	6.94	7.28	9.68	11.42
EPS (Adj) (Unit Curr.)	2.69	12.72	6.94	7.28	9.68	11.42
Calculated EPS (Unit Curr.)	2.69	12.72	7.71	7.76	9.68	11.43
Calculated EPS (Adj) (Unit Curr.)	2.69	12.72	7.71	7.76	9.68	11.43
Calculated EPS (Ann.) (Unit Curr.)	10.74	50.89	30.83	31.04	38.73	45.70
Calculated EPS (Adj) (Ann.) (Unit Curr.)	10.74	50.89	30.83	31.04	38.73	45.70
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	320.00	0.00	0.00	0.00	0.00
Equity	169.41	169.41	169.41	169.41	169.41	169.41
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	10.25	33.05	26.47	26.23	30.04	30.82
PBDTM(%)	10.21	33.00	26.43	26.14	30.03	30.77
PATM(%)	5.65	22.61	17.69	16.81	20.53	21.37

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	805.26	956.99	761.66	787.45	802.30	916.87
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	805.26	956.99	761.66	787.45	802.30	916.87
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	28.11	28.21	53.74	38.06	23.42	21.97
Total Income	833.37	985.20	815.40	825.51	825.72	938.84
Total Expenditure	750.51	667.50	617.78	617.71	584.97	659.94
PBIDT	82.86	317.70	197.62	207.80	240.75	278.90
Interest	0.32	0.43	0.28	0.65	0.09	0.39
PBDT	82.54	317.27	197.34	207.15	240.66	278.51
Depreciation	17.11	18.11	16.36	17.18	16.41	16.36
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	31.41	91.28	53.23	57.30	69.20	73.36
Deferred Tax	-11.70	-9.63	-4.50	-0.76	-9.51	-4.63
Reported Profit After Tax	45.72	217.51	132.25	133.43	164.56	193.42
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	45.72	217.51	132.25	133.43	164.56	193.42

Extra-ordinary Items	-131.90	0.00	12.21	7.26	-7.86	0.00
Adjusted Profit After Extra-ordinary item	177.62	217.51	120.04	126.17	172.42	193.42

EPS (Unit Curr.)	2.70	12.84	7.04	7.41	9.71	11.42
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	320.00	0.00	0.00	0.00	0.00
Equity	169.41	169.41	169.41	169.41	169.41	169.41

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	10.29	33.20	25.95	26.39	30.01	30.42
PBDTM(%)	10.25	33.15	25.91	26.31	30.00	30.38
PATM(%)	5.68	22.73	17.36	16.94	20.51	21.10

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	169.41	169.41	169.41	169.41	169.41	84.70
Reserves Total	1583.59	2508.21	1327.71	1670.63	1973.01	1995.25
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	1753.00	2677.62	1497.12	1840.04	2142.42	2079.95
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	15.54	20.08	34.63	0.18	0.58	0.99
Total Debt	15.54	20.08	34.63	0.18	0.58	0.99
Total Liabilities	1768.54	2697.70	1531.75	1840.22	2143.00	2080.94
APPLICATION OF FUNDS :
Gross Block	635.93	593.89	602.89	1454.59	561.30	408.14
Less : Accumulated Depreciation	305.99	263.26	216.00	696.53	129.69	83.57
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	329.94	330.63	386.89	758.06	431.61	324.57
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	20.31	30.50	13.21	120.12	1002.64	922.90
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	542.78	390.09	24.49	24.49	24.55	47.67
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	437.70	512.71	523.34	483.03	486.49	500.18
Sundry Debtors	192.38	205.24	215.60	99.80	120.49	146.96
Cash and Bank	1150.73	2479.11	1157.68	1066.41	1155.33	1279.69
Loans and Advances	167.62	108.05	274.71	107.54	228.87	236.21
Total Current Assets	1948.43	3305.12	2171.33	1756.78	1991.18	2163.05
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	590.94	1046.53	866.70	559.87	1205.15	1344.46
Provisions	713.99	615.36	438.35	442.04	245.32	251.18
Total Current Liabilities	1304.94	1661.90	1305.05	1001.92	1450.47	1595.64
Net Current Assets	643.49	1643.22	866.28	754.86	540.71	567.41
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	151.38	131.67	117.24	126.09	84.60	119.26
Deferred Tax Liability	18.20	18.89	15.57	17.24	24.12	16.20
Net Deferred Tax	133.18	112.78	101.67	108.85	60.48	103.06
Total Assets	1669.70	2507.22	1392.54	1766.38	2059.99	1965.61
Contingent Liabilities	350.59	351.10	485.78	471.42	512.80	637.85

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	169.41	169.41	169.41	169.41	169.41	84.70
Reserves Total	1571.87	2493.55	1308.85	1651.20	1970.42	1972.63
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	1741.28	2662.96	1478.26	1820.61	2139.83	2057.33
Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	15.54	20.08	34.63	0.18	0.58	0.99
Total Debt	15.54	20.08	34.63	0.18	0.58	0.99
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	255.49	264.27	261.56	290.65	316.99	289.71
Total Liabilities	2012.31	2947.31	1774.45	2111.44	2457.40	2348.03
APPLICATION OF FUNDS :
Gross Block	635.95	593.91	602.91	1454.62	561.32	408.16
Less: Accumulated Depreciation	305.99	263.26	216.00	696.53	129.69	83.57
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	329.96	330.65	386.91	758.09	431.63	324.59
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	20.31	30.50	13.21	120.12	1002.64	922.90
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	518.29	365.59	0.00	0.00	0.06	0.06
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	459.97	534.70	546.70	483.03	486.49	500.18
Sundry Debtors	192.38	205.24	215.60	99.80	120.49	146.96
Cash and Bank	1155.93	2484.51	1157.96	1083.20	1171.35	1296.41
Loans and Advances	167.70	118.00	282.37	108.85	231.13	242.85
Total Current Assets	1975.98	3342.44	2202.64	1774.89	2009.46	2186.41
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	600.29	1070.61	901.86	579.75	1208.12	1347.80
Provisions	713.99	615.36	438.35	442.04	245.79	251.66
Total Current Liabilities	1314.28	1685.97	1340.20	1021.80	1453.91	1599.46
Net Current Assets	661.70	1656.47	862.43	753.09	555.55	586.94
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	151.74	132.03	118.70	127.72	86.34	119.93
Deferred Tax Liability	18.20	18.89	15.57	17.24	24.12	16.20
Net Deferred Tax	133.54	113.14	103.13	110.48	62.22	103.73
Other Assets	348.50	450.95	408.76	369.66	405.30	409.81
Total Assets
Contingent Liabilities	353.87	354.78	491.05	476.68	534.01	669.66

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	280.79	404.90	98.03	97.78	199.40
Net Cash from Operating Activities	487.94	819.79	594.87	490.97	411.18
Net Cash Used In Investing Activities	805.19	-419.66	407.57	-63.10	-154.44
Net Cash Used In Financing Activities	-1544.18	-524.24	-695.56	-427.62	-358.36
Net Inc./Dec In Cash And Cash Equivalents	-251.05	-124.11	306.87	0.25	-101.62
Cash And Cash Equivalents At End Of The Year	29.74	280.79	404.90	98.03	97.78

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

75.00%

FII Shareholding

3.48%

DII Shareholding

7.90%

Public Shareholding

13.62%

**Promoter pledged shareholding 75.00%

About Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 35471.08 crores. It has reported a sales of Rs. 804.98 crores and a net profit of Rs. 45.49 crores for the quarter ended December 2018. The company management includes Renu S Karnad, D Sundaram,A A Nadkarni,P V Bhide,A N Roy,Subesh Williams,Renu S Karnad,Sunita Maheshwari,Manu Anand,Bhushan Akshikar,J. Chandy (Glaxosmithkline Pharmaceuticals Ltd) among others.

Chairman

Renu S Karnad

Registered office

GSK House,Dr Annie Besant Road Worli,Mumbai,Maharashtra,400030

FAX :91-022-24959494

Background

Incorporation Year1924

Face Value₹10

Market Lot1

How to buy Glaxosmi. Pharma shares on nse?

To buy Glaxosmi. Pharma shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Glaxosmi. Pharma share price today?

The Glaxosmi. Pharma shares price on nse is Rs.2093.85 today.

What is the market cap of Glaxosmi. Pharma shares on BSE ?

The company has a market capitalization of Rs.35471.08Cr

What is the PE & PB ratio of Glaxosmi. Pharma shares ?

PE is 55.81 and PB is 22.92

What is the 52 Week High and Low of Glaxosmi. Pharma shares?

Glaxosmi. Pharma stock price high: Rs.2649.95 Glaxosmi. Pharma stock price low: Rs.1242

What is the correct way to invest in Glaxosmith?

The correct way to invest in GlaxoSmithKline Pharmaceuticals is to buy the shares of the company through a reputed broker like Motilal Oswal. You can sign up with the broker online and open a dreamt and trading account first. Then, you can place an order to buy the company stock through the broker and invest in the company.

How can I sell Glaxosmith Pharma shares?

To sell GlaxoSmithKline Pharmaceutical shares you must be signed up with a broker like Motilal Oswal. Shares must be held in a demat account to be sold. You also need to have a trading account linked to your demat account. Once you place a sell request with your broker, your shares are sold and the proceeds are credited to your bank account linked with your demat and trading accounts.

What is the ROI of Glaxosmith Pharma shares?

The current year ROI (YTD 17 April 2023) of GlaxoSmithKline Pharmaceutical shares is -3.81%.

Can I buy Glaxosmith Pharma shares now?

You can buy the shares of GlaxoSmithKline Pharmaceuticals now or at any time through a reputed broker like Motilal Oswal. All you require is a demat account linked with a trading account. These two accounts are connected to your bank account and you can easily place a buy order with your broker to buy the shares you want.

What is the trending volume of Glaxosmith Pharma shares?

The trading volume of GlaxoSmithKline Pharmaceutical shares is 53,700 (17 April 2023).